Over-Expression of ARID3B Suppresses Tumor Progression and Predicts Better Prognosis in Patients With Gastric Cancer

Background ARID3B (AT-rich interaction domain 3B) has been demonstrated to be associated with the progression and patient prognosis of several human tumors. We conducted the present study to investigate the biological behavior and clinical relevance of ARID3B in gastric cancer (GC). Methods Detection of the expression level in GC tissues and cell lines were performed by Western blot and immunohistochemistry. We also retrospectively analyzed the correlation of ARID3B with clinicopathological characteristics and patient prognosis in gastric cancer. The biological functions of ARID3B in GC cells were further explored by transwell migration assays, wound healing assays and cell proliferation assay. Results The present study suggested that the expression of ARID3B was significantly lower in GC tissues than in adjacent normal tissues. IHC staining in tissues of 406 GC patients from training and validation sets verified that ARID3B over-expression correlated with clinicopathological features, such as degree of differentiation and clinical stage. Meanwhile, ARID3B was proved to be an independent prognostic factor for GC prognosis. Furthermore, over-expression of ARID3B suppressed proliferation in GC cells according CCK8 assay. We found that over-expression of ARID3B inhibited GC cell migration by transwell assay and wound healing assay. Furthermore, EMT markers were detected in ARID3B over-expression GC cells, which showed that ARID3B may inhibit metastasis of GC cells. Conclusion Our results firstly revealed that the expression level of ARID3B was closely correlated with clinicopathological features and may serve as an independent prognostic factor for GC patients. More importantly, ARID3B could suppress GC progression, including cell proliferation, migration and metastasis.

[1]  D. Pang,et al.  Expression and prognostic values of ARID family members in breast cancer , 2021, Aging.

[2]  C. Ulrich,et al.  Genotype-Based Gene Expression in Colon Tissue—Prediction Accuracy and Relationship with the Prognosis of Colorectal Cancer Patients , 2020, International journal of molecular sciences.

[3]  Karen D. Cowden Dahl,et al.  ARID3A and ARID3B induce stem promoting pathways in ovarian cancer cells. , 2020, Gene.

[4]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[5]  You-hong Cui,et al.  AEBP1 promotes epithelial-mesenchymal transition of gastric cancer cells by activating the NF-κB pathway and predicts poor outcome of the patients , 2018, Scientific Reports.

[6]  J. Yamamoto,et al.  Efficacy of totally laparoscopic distal gastrectomy for gastric cancer in elderly patients. , 2016, Molecular and clinical oncology.

[7]  Endrawan Pratama,et al.  Critical role of ARID3B in the expression of pro-apoptotic p53-target genes and apoptosis. , 2015, Biochemical and biophysical research communications.

[8]  Jian-jun Xiao,et al.  Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. , 2015, Translational research : the journal of laboratory and clinical medicine.

[9]  Jun Yu Li,et al.  ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature , 2014, Oncotarget.

[10]  Karen D. Cowden Dahl,et al.  Differential expression of ARID3B in normal adult tissue and carcinomas. , 2014, Gene.

[11]  R. Ward,et al.  The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells , 2013, PloS one.

[12]  H. Xi,et al.  Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival , 2012, World Journal of Surgical Oncology.

[13]  Karen D. Cowden Dahl,et al.  ARID3B Induces Tumor Necrosis Factor Alpha Mediated Apoptosis While a Novel ARID3B Splice Form Does Not Induce Cell Death , 2012, PloS one.

[14]  S. Nishikawa,et al.  Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn , 2012, Oncogene.

[15]  C. Schmidt,et al.  Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription. , 2011, Molecular immunology.

[16]  Miguel Torres,et al.  Apical ectodermal ridge morphogenesis in limb development is controlled by Arid3b-mediated regulation of cell movements , 2011, Development.

[17]  Carlos Resende,et al.  Genetic and Epigenetic Alteration in Gastric Carcinogenesis , 2010, Helicobacter.

[18]  Karen D. Cowden Dahl,et al.  The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. , 2009, Neoplasia.

[19]  A. Panani.  Cytogenetic and molecular aspects of gastric cancer: clinical implications. , 2008, Cancer letters.

[20]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[21]  Stuart H. Orkin,et al.  A protein interaction network for pluripotency of embryonic stem cells , 2006, Nature.

[22]  S. Nishikawa,et al.  Microarray analysis of PDGFR alpha+ populations in ES cell differentiation culture identifies genes involved in differentiation of mesoderm and mesenchyme including ARID3b that is essential for development of embryonic mesenchymal cells. , 2006, Developmental biology.

[23]  J. Weinstein,et al.  Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.

[24]  E. Moran,et al.  Nomenclature of the ARID family of DNA-binding proteins. , 2005, Genomics.

[25]  S. Sekiya,et al.  A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer , 1998, Oncogene.

[26]  R. Saint,et al.  The human dead ringer/bright homolog, DRIL1: cDNA cloning, gene structure, and mapping to D19S886, a marker on 19p13.3 that is strictly linked to the Peutz-Jeghers syndrome. , 1998, Genomics.

[27]  R. Scheuermann,et al.  The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: a B cell-specific trans-activator that describes a new DNA-binding protein family. , 1995, Genes & development.

[28]  A. E. Erson-Bensan,et al.  miR-125b targets ARID3B in breast cancer cells. , 2012, Cell structure and function.